Peel Hunt reissued their buy rating on shares of Motif Bio (LON:MTFB) in a research note issued to investors on Wednesday morning. The firm currently has a GBX 107 ($1.45) target price on the stock.
Several other analysts have also recently issued reports on the stock. FinnCap restated a buy rating and set a GBX 100 ($1.36) target price on shares of Motif Bio in a research report on Wednesday, November 22nd. Northland Securities restated a buy rating on shares of Motif Bio in a research report on Wednesday, November 15th. Finally, Beaufort Securities restated a speculative buy rating and set a GBX 110 ($1.49) target price on shares of Motif Bio in a research report on Thursday, November 16th.
Shares of Motif Bio (LON:MTFB) traded up GBX 0.35 ($0.00) during midday trading on Wednesday, hitting GBX 41.10 ($0.56). 608,849 shares of the stock traded hands, compared to its average volume of 886,306. The stock has a market cap of $108.06 and a PE ratio of -152.22. Motif Bio has a 52-week low of GBX 22.50 ($0.31) and a 52-week high of GBX 51.75 ($0.70).
TRADEMARK VIOLATION WARNING: “Motif Bio’s (MTFB) Buy Rating Reaffirmed at Peel Hunt” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/01/14/motif-bios-mtfb-buy-rating-reaffirmed-at-peel-hunt-2.html.
Motif Bio Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.